Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 113 entries
Sorted by: Best Match Show Resources per page
[In Process Citation].

Orvosi hetilap

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.
PMID: 26667112
Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331.

Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further...

Cite
Horváth G, Gerlei Z, Gervain J, et al. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015;156:25-36doi: 10.1556/OH.2015.30331.
Horváth, G., Gerlei, Z., Gervain, J., Lengyel, G., Makara, M., Pár, A., Rókusz, L., Szalay, F., Tornai, I., Werling, K., & Hunyady, B. (2015). A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orvosi hetilap, 15625-36. https://doi.org/10.1556/OH.2015.30331
Horváth, Gábor, et al. "A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től." [In Process Citation]. Orvosi hetilap vol. 156 (2015): 25-36. doi: https://doi.org/10.1556/OH.2015.30331
Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331. Hungarian. PMID: 26667112.
Copy Download .nbib Format: NLM
Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs.

Hepatology research : the official journal of the Japan Society of Hepatology

Zhang Y, Li J, Li F, Qi X, Zhang J.
PMID: 28452097
Hepatol Res. 2018 Feb;48(2):144-152. doi: 10.1111/hepr.12908. Epub 2017 Jun 29.

AIM: Little is known about the impact of long-term use of nucleos(t)ide analogs on tubular function in patients with chronic hepatitis B. Previous studies showed that neutrophil gelatinase-associated lipocalin (NGAL) elevation was associated with renal tubular injury. We evaluated...

Cite
Zhang Y, Li J, Li F, et al. Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. Hepatol Res. 2017;48(2):144-152doi: 10.1111/hepr.12908.
Zhang, Y., Li, J., Li, F., Qi, X., & Zhang, J. (2018). Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. Hepatology research : the official journal of the Japan Society of Hepatology, 48(2), 144-152. https://doi.org/10.1111/hepr.12908
Zhang, Yao, et al. "Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,2 (2018): 144-152. doi: https://doi.org/10.1111/hepr.12908
Zhang Y, Li J, Li F, Qi X, Zhang J. Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. Hepatol Res. 2018 Feb;48(2):144-152. doi: 10.1111/hepr.12908. Epub 2017 Jun 29. PMID: 28452097.
Copy Download .nbib Format: NLM
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

World journal of virology

Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW.
PMID: 24175223
World J Virol. 2012 Dec 12;1(6):174-83. doi: 10.5501/wjv.v1.i6.174.

Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma (HCC) in patients chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). The approved medication for the treatment of chronic HBV...

Cite
Chen LP, Zhao J, Du Y, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012;1(6):174-83doi: 10.5501/wjv.v1.i6.174.
Chen, L. P., Zhao, J., Du, Y., Han, Y. F., Su, T., Zhang, H. W., & Cao, G. W. (2012). Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World journal of virology, 1(6), 174-83. https://doi.org/10.5501/wjv.v1.i6.174
Chen, Li-Ping, et al. "Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma." World journal of virology vol. 1,6 (2012): 174-83. doi: https://doi.org/10.5501/wjv.v1.i6.174
Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012 Dec 12;1(6):174-83. doi: 10.5501/wjv.v1.i6.174. PMID: 24175223; PMCID: PMC3782279.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 15148527
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004;26(3):211-44
Bayés, M., Rabasseda, X., & Prous, J. R. (2004). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 26(3), 211-44.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 26,3 (2004): 211-44.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PMID: 15148527.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18985183
Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(7):543-88
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(7), 543-88.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,7 (2008): 543-88.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PMID: 18985183.
Copy Download .nbib Format: NLM
Advances in Molecular Diagnosis of HBV Infection and Drug Resistance.

International journal of medical sciences

Sablon E, Shapiro F.
PMID: 15968334
Int J Med Sci. 2005;2(1):8-16. doi: 10.7150/ijms.2.8. Epub 2005 Jan 05.

Serological markers are key elements in diagnosing acute hepatitis B virus (HBV) infection and determining its possible evolution towards chronicity. Once treatment of chronic HBV is initiated with approved anti-hepadnaviral agents, such as lamivudine, interferon-alpha, or adefovir dipivoxil, the...

Cite
Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2(1):8-16doi: 10.7150/ijms.2.8.
Sablon, E., & Shapiro, F. (2005). Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. International journal of medical sciences, 2(1), 8-16. https://doi.org/10.7150/ijms.2.8
Sablon, Erwin, and Shapiro, Fred. "Advances in Molecular Diagnosis of HBV Infection and Drug Resistance." International journal of medical sciences vol. 2,1 (2005): 8-16. doi: https://doi.org/10.7150/ijms.2.8
Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2(1):8-16. doi: 10.7150/ijms.2.8. Epub 2005 Jan 05. PMID: 15968334; PMCID: PMC1142219.
Copy Download .nbib Format: NLM
Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18850047
Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95.

(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept, Aliskiren fumarate, Apixaban, Atazanavir sulfate, Atrasentan, Axitinib; BI-1744-CL, BIBF-1120, BIBW-2992, Bortezomib; Carboxyamidotriazole, Caspofungin acetate, CBP-501, Cediranib, Ceftobiprole, Certolizumab pegol, Cetuximab, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, CHP-NY-ESO-1, Cypher;...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008;30(6):459-95
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. July-August 2008. Methods and findings in experimental and clinical pharmacology, 30(6), 459-95.
Tomillero, A, and Moral, M A. "Gateways to clinical trials. July-August 2008." Methods and findings in experimental and clinical pharmacology vol. 30,6 (2008): 459-95.
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PMID: 18850047.
Copy Download .nbib Format: NLM
New approaches in the management of chronic hepatitis B: role of tenofovir.

Infection and drug resistance

Reijnders JG, LA Janssen H.
PMID: 21694884
Infect Drug Resist. 2009;2:13-26. doi: 10.2147/idr.s3918. Epub 2009 Apr 24.

In the field of HIV management, tenofovir disoproxil fumarate (TDF) plays a pivotal role and has been demonstrated to be a safe and well-tolerated antiviral agent. Recent data showed the efficacy of TDF in the treatment of chronically hepatitis...

Cite
Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist. 2009;2:13-26doi: 10.2147/idr.s3918.
Reijnders, J. G., & LA Janssen, H. (2009). New approaches in the management of chronic hepatitis B: role of tenofovir. Infection and drug resistance, 213-26. https://doi.org/10.2147/idr.s3918
Reijnders, Jurriën Gp, and LA Janssen, Harry. "New approaches in the management of chronic hepatitis B: role of tenofovir." Infection and drug resistance vol. 2 (2009): 13-26. doi: https://doi.org/10.2147/idr.s3918
Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist. 2009;2:13-26. doi: 10.2147/idr.s3918. Epub 2009 Apr 24. PMID: 21694884; PMCID: PMC3108728.
Copy Download .nbib Format: NLM
Treatment of Hepatitis B e Antigen-negative Patients.

Current treatment options in gastroenterology

Hui CK, Lau GK.
PMID: 18221608
Curr Treat Options Gastroenterol. 2007 Dec;10(6):474-82. doi: 10.1007/s11938-007-0047-6.

Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) occurs at the late phase in hepatitis B virus (HBV) infection's natural history. The disease is characterized by progressive liver damage due to variants with mutations in the precore/core promoter...

Cite
Hui CK, Lau GK. Treatment of Hepatitis B e Antigen-negative Patients. Curr Treat Options Gastroenterol. 2007;10(6):474-82doi: 10.1007/s11938-007-0047-6.
Hui, C. K., & Lau, G. K. (2007). Treatment of Hepatitis B e Antigen-negative Patients. Current treatment options in gastroenterology, 10(6), 474-82. https://doi.org/10.1007/s11938-007-0047-6
Hui, Chee-Kin, and Lau, George K. "Treatment of Hepatitis B e Antigen-negative Patients." Current treatment options in gastroenterology vol. 10,6 (2007): 474-82. doi: https://doi.org/10.1007/s11938-007-0047-6
Hui CK, Lau GK. Treatment of Hepatitis B e Antigen-negative Patients. Curr Treat Options Gastroenterol. 2007 Dec;10(6):474-82. doi: 10.1007/s11938-007-0047-6. PMID: 18221608.
Copy Download .nbib Format: NLM
Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B.

Hepatology international

Piratvisuth T.
PMID: 19669298
Hepatol Int. 2008 Jun;2(2):140-6. doi: 10.1007/s12072-008-9046-5. Epub 2008 Mar 04.

The primary aim of immunomodulator therapy is to help the natural human immune system to mount a defense against hepatitis B virus. IFN-alpha has been used for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B for over two...

Cite
Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int. 2008;2(2):140-6doi: 10.1007/s12072-008-9046-5.
Piratvisuth, T. (2008). Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatology international, 2(2), 140-6. https://doi.org/10.1007/s12072-008-9046-5
Piratvisuth, Teerha. "Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B." Hepatology international vol. 2,2 (2008): 140-6. doi: https://doi.org/10.1007/s12072-008-9046-5
Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int. 2008 Jun;2(2):140-6. doi: 10.1007/s12072-008-9046-5. Epub 2008 Mar 04. PMID: 19669298; PMCID: PMC2716848.
Copy Download .nbib Format: NLM
Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV).

Hepatology international

Hann HW, Chae HB, Dunn SR.
PMID: 19669311
Hepatol Int. 2008 Jun;2(2):244-9. doi: 10.1007/s12072-008-9045-6. Epub 2008 Feb 28.

OBJECTIVES: We retrospectively compared the antiviral effect of tenofovir disoproxil fumarate (TDF) with that of adefovir dipivoxil (ADV) for patients with chronic hepatitis B (CHB) who developed resistance to lamivudine (LAM).MATERIALS AND METHODS: One hundred nine patients (86 males),...

Cite
Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008;2(2):244-9doi: 10.1007/s12072-008-9045-6.
Hann, H. W., Chae, H. B., & Dunn, S. R. (2008). Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatology international, 2(2), 244-9. https://doi.org/10.1007/s12072-008-9045-6
Hann, Hie-Won, et al. "Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)." Hepatology international vol. 2,2 (2008): 244-9. doi: https://doi.org/10.1007/s12072-008-9045-6
Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008 Jun;2(2):244-9. doi: 10.1007/s12072-008-9045-6. Epub 2008 Feb 28. PMID: 19669311; PMCID: PMC2716857.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16082427
Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(4):265-84
Bayes, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(4), 265-84.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,4 (2005): 265-84.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84. PMID: 16082427.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 113 entries